In this study, we evaluated the in silico predictions of BRCA1 and BRCA2 CIP/VUS alterations in a cohort of BC patients, according to the ENIGMA or ClinVar database, using PolyPhen-2, SIFT, MT and PROVEAN tools. This evidence concerns the gene BRCA2 and breast cancer.